泰格医药(300347):订单稳步恢复,期待创新药政策逐步发力
ZHONGTAI SECURITIES·2025-05-11 12:38

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a slight decline in revenue for Q1 2025, with total revenue of 1.564 billion yuan, down 5.79% year-on-year, and a net profit attributable to shareholders of 165 million yuan, down 29.61% year-on-year [6] - New orders are gradually recovering, with a significant increase in new contract amounts, exceeding 2 billion yuan in Q1 2025, representing a 20% year-on-year growth [6] - The gross margin is showing signs of recovery, with Q1 2024 gross margin at approximately 30.03%, an increase of 12.34 percentage points quarter-on-quarter [6] - The company is expected to see revenue growth from 2025 to 2027, with projected revenues of 71.11 billion, 78.79 billion, and 89.07 billion yuan, reflecting year-on-year growth rates of 7.69%, 10.80%, and 13.05% respectively [6] - The net profit attributable to shareholders is forecasted to be 1.08 billion, 1.26 billion, and 1.48 billion yuan for the years 2025 to 2027, with significant growth rates of 166.69%, 16.78%, and 17.57% respectively [6] Financial Summary - The company has a total share capital of 864.95 million shares and a market price of 44.79 yuan, resulting in a market capitalization of approximately 38.74 billion yuan [4] - The projected earnings per share (EPS) for 2025 is 1.25 yuan, with a price-to-earnings (P/E) ratio of 35.85 [4] - The return on equity (ROE) is expected to improve from 1.96% in 2024 to 6.07% in 2027 [4]

Tigermed-泰格医药(300347):订单稳步恢复,期待创新药政策逐步发力 - Reportify